Skip to content
WebHeader_ASTRO ver3
Visit Our Booth In The Exhibit Hall
Stop by the GammaTile booth to learn more about GammaTile and see the latest data.
ASTRO 2025 Day 2-00_00_08_10-Still001
Industry Expert Theater
Improved Local Control and Survival: Phase 3 Evidence for Tile-Based Radiation in Brain Metastases
See the breakthrough findings of ROADS, the phase 3 randomized trial showing the superiority of tile-based radiation therapy.

Time: 12:00 - 1:00 PM
Date: Sunday, September 27, 2026
Location: Green Theater, Exhibit  Hall

260716-KM-MSK-IMBER-8711

Brandon Imber, MD, MA
Assistant Attending Radiation Oncologist
Memorial Sloan Kettering Cancer Center

Headshots for HS (4)

Lindsey Sloan, MD, PhD
Associate Professor, Department of Radiation Oncology
Radiobiologist, Masonic Cancer Center
Sloan Laboratory, University of Minnesota Brain Tumor Program
University of Minnesota Medical School

GammaTile Clinical Dinner Symposium
Closing the Treatment Gap: How the ROADS Data is Revolutionizing the Future of Operable Brain Tumor Radiation Therapy
The gap between resection and adjuvant radiation has continued to be a challenge for brain metastasis care. Industry leaders will present on how Tile-Based Radiation Therapy (TBRT) with GammaTile is revolutionizing treatment timing and local control by closing The Treatment Gap.

Join us on the waterfront for a candid look at the ROADS RCT data and best practices for TBRT integration.

Time: 6:30 PM
Date: Sunday, September 27, 2026
Location: The Exchange, 212 Northern Ave, Boston, MA

Headshots for HS (4)

Lindsey Sloan, MD, PhD
Associate Professor, Department of Radiation Oncology
Radiobiologist, Masonic Cancer Center
Sloan Laboratory, University of Minnesota Brain Tumor Program
University of Minnesota Medical School

Matthew Sean Peach MD PhD_Ashley Hupman

M. Sean Peach, MD, PhD
Associate Professor, The Brody School of Medicine at East Carolina University
Director of Brachytherapy Services, ECU Health

Poster Presentations
Tile-Based Radiation Therapy for Upfront Treatment of Grade 4 Gliomas in Patients =70 Years and/or Low KPS: Prospective Multi-Institutional Outcomes
3:00 - 4:00 PM ET • September 27 • Poster Hall, Exhibit Hall A
The Influence of Payer Type vs. Community Characteristics in Shaping Realized Access to Proton Therapy
2:15 - 3:30 PM ET • September 29 • Poster Hall, Exhibit Hall A
Delay vs. Non-Receipt of Post-Craniotomy Radiation Therapy: Association of Facility Availability, Proximity, and Social Vulnerability
2:15 - 3:30 PM ET • September 29 • Poster Hall, Exhibit Hall A
Medicare Advantage Representation at U.S. Proton Therapy Centers Relative to Catchment-Weighted Benchmarks
2:15 - 3:30 PM ET • September 29 • Poster Hall, Exhibit Hall A